会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明授权
    • Multi-transmitter interferometry
    • 多发射干涉测量
    • US08159387B1
    • 2012-04-17
    • US12798170
    • 2010-03-15
    • Jose FernandezRichard RikoskiJohn Stroud
    • Jose FernandezRichard RikoskiJohn Stroud
    • G01S13/42G01S3/80
    • G01S15/46G01S13/48
    • Systems and methods for obtaining target elevation information are disclosed. The systems and methods use multiple vertical transmitters and one or more receivers to infer changes in the elevation plane and the height of objects. Changes in elevation and heights of objects are inferred from path length differences between the transmitters and a particular backscattering point. Using known geometric information regarding the configuration of the transmitters, propagation time differences can be estimated via time delay estimation methods in either the time or frequency domain. Appropriate modulation schemes are used such that the multiple signals transmitted are separable upon reception.
    • 公开了用于获得目标高程信息的系统和方法。 系统和方法使用多个垂直发射器和一个或多个接收器来推断仰角平面中的变化和物体的高度。 物体高程和高度的变化由发射机与特定的后向散射点之间的路径长度差异推断出来。 使用关于发射机的配置的已知几何信息,可以通过时域或频域中的时间延迟估计方法估计传播时间差。 使用适当的调制方案,使得发送的多个信号在接收时是可分离的。
    • 5. 发明授权
    • Plasma glucosylceramide deficiency as risk factor for thrombosis and modulator of anticoagulant protein C
    • 血浆葡萄糖神经酰胺缺乏作为血栓形成的危险因素和抗凝血蛋白C的调节剂
    • US06756208B2
    • 2004-06-29
    • US10086943
    • 2002-02-28
    • John H. GriffinHiroshi DeguchiJose Fernandez
    • John H. GriffinHiroshi DeguchiJose Fernandez
    • C12Q156
    • C07H15/10A61K31/739
    • The present invention has determined that exogenously added glycosylceramide (GlcCer) and other neutral glycolipids such as the homologous Glc-containing globotriaosylceramide (Gb3Cer), dose-dependently prolonged clotting times of normal plasma in the presence but not absence of APC:protein S, indicating GlcCer or Gb3Cer can enhance protein C pathway anticoagulant activity. In studies using purified proteins, inactivation of factor Va by APC:protein S was enhanced by GlcCer alone and by GlcCer, globotriaosylceramide, lactosylceramide, and galactosylceramide in multicomponent vesicles containing phosphatidylserine and phosphatidylcholine. Thus, the present invention provides neutral glycolipids such as GlcCer and Gb3Cer, as anticoagulant cofactors that contribute to the antithrombotic activity of the protein C pathway. The present invention has also determined that a deficiency of plasma GlcCer is a risk factor for thrombosis. Methods are provided to determine individuals at risk for thrombosis, methods of treatment as well as methods of screening for antithrombotic factors from neutral glycolipids.
    • 本发明已经确定外源性加入的糖基神经酰胺(GlcCer)和其它中性糖脂如同源的含Glc的球三孢甲酸神经酰胺(Gb3Cer)在APC存在但不存在APC蛋白S的情况下剂量依赖地延长正常血浆的凝血时间,表明 GlcCer或Gb3Cer可增强蛋白C通路的抗凝活性。 在使用纯化的蛋白质的研究中,通过GlcCer单独的GlcCer,GlcCer,globotriaosylceramide,乳糖神经酰胺和半乳糖神经酰胺在含有磷脂酰丝氨酸和磷脂酰胆碱的多组分囊泡中增强了APC因子Va的失活:蛋白S。 因此,本发明提供中性糖脂如GlcCer和Gb3Cer作为有助于蛋白C途径的抗血栓形成活性的抗凝血辅助因子。 本发明还确定血浆GlcCer的不足是血栓形成的危险因素。 提供方法来确定处于血栓形成风险的个体,治疗方法以及从中性糖脂中筛选抗血栓形成因子的方法。